Researchers Find Method to Repurpose Immune Cells
Blocking the TET2 enzyme improves the efficacy of radiation and immunotherapy treatments for cancer.
Updated on Oct. 30, 2026 in Cancer
Live Poll
Do you believe new cancer treatment research will meaningfully improve care for the average patient?
A study published in August 2026 identifies a biological mechanism that allows immune cells to attack tumors by blocking the TET2 enzyme. This intervention aims to reverse immune suppression caused by radiation therapy.
Why it matters
Radiation often triggers the body to produce myeloid-derived suppressor cells that shield tumors from attack, hindering treatment success. Blocking TET2 keeps the immune system alert and capable of targeting cancer cells effectively.
Approximately 50% to 60% of cancer patients receive radiation therapy as part of their treatment plan. Researchers analyzed immune responses in 33 patients with stage IV lung cancer to confirm the role of TET2 activity.
The players
University of Chicago
This academic institution served as the primary site for the research into tumor immune cell behavior.
UChicago Medicine
This health system is preparing for the expansion of its clinical research facilities in Chicago.
The details
Radiation therapy activates the p53 protein, which triggers TET2 to remove chemical tags from RNA and silence interferon pathways that signal threats to the immune system. Experimental inhibitors that block TET2 allow myeloid cells to mature into activating cells that prime CD8+ T cells to attack cancer instead of protecting it.
Timeline
August 2026: The research findings were published in a peer-reviewed journal.
October 30, 2026: The study results were formally released.
April 2027: UChicago Medicine is scheduled to open the AbbVie Foundation Cancer Pavilion.
The Big Picture
This discovery marks a shift in oncology toward modulating the tumor microenvironment through precise molecular intervention. It parallels the development of targeted therapies like the ORION-10 statin trial by moving beyond broad systemic treatments to specific enzyme-based control.
This development could lead to future clinical trials where patients receive TET2 inhibitors alongside standard radiation to improve treatment response. These findings offer a potential strategy for patients with advanced cancers currently resistant to traditional therapies.
The takeaway
Researchers are currently evaluating how to combine experimental TET2 inhibitors with radiation to maximize anti-tumor responses in clinical settings. Patients should discuss existing immunotherapy options with their oncologists as these technologies continue to move toward human testing.
What happens next
UChicago Medicine will open the AbbVie Foundation Cancer Pavilion in April 2027 to further its research and patient care initiatives.
Further reading
Learn more about the latest research in our Cancer section.
More information
View the full results in the Cancer Cell study abstract00394-6).
Source note: This article includes information reported by News-Medical.
Live Poll
Do you believe new cancer treatment research will meaningfully improve care for the average patient?
